Revelation Biosciences Q2 2023 net loss $1.4M; cash $15.7M; 6-month net income $4.7M on warrant gain

REVELATION BIOSCIENCES, INC.

2023-Q2 EPS reported $1.53

Cash and cash equivalents of $15.7M as of June 30, 2023, up from $5.3M at Dec 31, 2022.
Net loss for Q2 2023 was $1.4M ($0.25 per share) vs $1.8M ($4.16 per share) in Q2 2022.
Net income for 6 months ended June 30, 2023 was $4.7M ($1.61 basic EPS) vs net loss of $8.5M in prior period, driven by $8.2M warrant liability gain.
Net cash used for operating activities for 6 months ended June 30, 2023 was $3.6M, down from $8.5M year-over-year.
Management believes current cash sufficient to fund operations through June 2024; decreased clinical study expenses contributed to lower losses.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

REVELATION BIOSCIENCES, INC. reported the three and six months ended June 30, 2023 results: net income net loss of $1.4 million, or $0.25 basic and diluted net loss per share, EPS $0.25 basic and diluted net loss per share.

Period: the three and six months ended June 30, 2023
Net income: net loss of $1.4 million, or $0.25 basic and diluted net loss per share
EPS: $0.25 basic and diluted net loss per share
Result: reported results

Exact text from the filing

On August 11, 2023, Revelation Biosciences, Inc. issued a press release announcing its financial results for the three and six months ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

REVELATION BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-041889

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.